The FDA rolls out its own AI to speed up clinical reviews and scientific evaluations

The FDA has launched Elsa, an AI tool designed to streamline tasks like clinical reviews and investigations, inspired by the snow queen from *Frozen*. This innovative platform can analyze adverse events, generate summaries, compare labels, and create codes, aiding in speeding up processes such as protocol reviews. While concerned about security, the FDA assures Elsa operates internally without public data. As the first AI initiative, Elsa highlights a shift at the FDA towards leveraging technology to enhance efficiency.